Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Selectis Health (GBCS) Shares Outstanding (Diluted Average) (2017 - 2025)

Selectis Health's Shares Outstanding (Diluted Average) history spans 14 years, with the latest figure at $3.1 million for Q3 2025.

  • For Q3 2025, Shares Outstanding (Diluted Average) changed 0.0% year-over-year to $3.1 million; the TTM value through Sep 2025 reached $3.1 million, changed 0.0%, while the annual FY2024 figure was $3.1 million, 0.41% changed from the prior year.
  • Shares Outstanding (Diluted Average) for Q3 2025 was $3.1 million at Selectis Health, roughly flat from $3.1 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $3.1 million in Q1 2024 and bottomed at $2.7 million in Q2 2021.
  • The 5-year median for Shares Outstanding (Diluted Average) is $3.1 million (2023), against an average of $3.0 million.
  • The largest annual shift saw Shares Outstanding (Diluted Average) plummeted 90.33% in 2021 before it increased 13.59% in 2022.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $2.8 million in 2021, then grew by 10.33% to $3.1 million in 2022, then increased by 0.02% to $3.1 million in 2023, then rose by 0.41% to $3.1 million in 2024, then changed by 0.0% to $3.1 million in 2025.
  • Per Business Quant, the three most recent readings for GBCS's Shares Outstanding (Diluted Average) are $3.1 million (Q3 2025), $3.1 million (Q2 2025), and $3.1 million (Q1 2025).